Moxonidine canon 0.4 mg 60 pcs. film-coated tablets

Moxonidine ~ Alpha2-adrenomimetic central

Price in pharmacies from 89.00 to 376.30 rubles*

A selective agonist of imidazoline receptors, is involved in the tonic and reflex regulation of the sympathetic nervous system (localized in the ventrolateral medulla oblongata). Reduces the pressor effect of the sympathetic system on peripheral vessels, reduces peripheral vascular resistance, reduces systolic and diastolic blood pressure (BP) both with a single dose and with long-term use, while cardiac output and heart rate (HR) do not change significantly . With long-term use, it reduces left ventricular myocardial hypertrophy, smoothes out the signs of myocardial fibrosis, microarteriopathy, and normalizes capillary blood supply to the myocardium. During treatment, the activity of norepinephrine and epinephrine, renin, angiotensin II at rest and during exercise, atrial natriuretic peptide (with exercise) and plasma aldosterone decreases. More about the drug »

ATTENTION! ALWAYS check with your doctor or pharmacist to see if the found analogue can serve as a full replacement for the drug prescribed to you or the drug you are looking for. This is due to the need to use the dosage forms and doses prescribed specifically for you, which may differ even among analogues (more about analogues of drugs).

pharmachologic effect

Manufacturer: Severnaya Zvezda and others, Russia
Release form: tablets

Active ingredient: moxonidine

The drug contains the active ingredient of the same name – moxonidine. The drug is an antihypertensive, which has a central mechanism of action. With regular use, there is an improvement in the patient's condition, as well as stabilization of blood pressure.

Moxonidine - instructions for use

According to the instructions for use, Moxonidine is intended for oral use.

The dosage and duration of therapy is adjusted by the cardiologist and depends on the general condition of the patient.

If a negative reaction occurs, it is necessary to exclude independent interruption of treatment and seek additional advice from a specialist.

It is recommended to start therapy with a dosage of Moxonidine 0.2 mg per day. You are allowed to consume no more than 0.4 mg at a time. It is recommended to swallow the tablets and drink plenty of water.

As for patients with renal failure, in this situation additional consultation with a urologist is required.

How to take Moxonidine: before or after meals

It is allowed to take both before and after meals. Food has no effect on pharmacokinetics. If you take the tablets before meals, it is better to do it 30–40 minutes before or 45–60 minutes after.

MOXONIDINE CANON TAB P.P.O. 400mkg N28

Suction.

After oral administration, moxonidine is rapidly and almost completely absorbed from the upper gastrointestinal tract. Absolute bioavailability is approximately 88%. Tmax is about 1 hour. Food intake does not affect the pharmacokinetics of the drug.

Distribution.

The binding to plasma proteins is 7.2%.

Metabolism.

The main metabolite is dehydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine is about 10% of that of moxonidine.

Excretion.

T1/2 of moxonidine and metabolite is 2.5 and 5 hours, respectively. Within 24 hours, over 90% of moxonidine is excreted by the kidneys (about 78% unchanged and 13% as dehydromoxonidine, other metabolites in the urine do not exceed 8% of the dose taken). Less than 1% of the dose is excreted through the intestines.

Special patient groups

Arterial hypertension.

Compared with healthy volunteers, patients with arterial hypertension do not show changes in the pharmacokinetics of moxonidine.

Elderly age.

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine were noted in elderly patients, probably due to a decrease in the intensity of its metabolism and/or slightly higher bioavailability.

Children.

Moxonidine is not recommended for use in patients under 18 years of age, and therefore pharmacokinetic studies have not been conducted in this group.

Kidney failure.

Moxonidine excretion is significantly correlated with creatinine clearance. In patients with moderate renal failure (Cl creatinine 30–60 ml/min), plasma Css and final T1/2 are approximately 2 and 1.5 times higher than in patients with normal renal function (Cl creatinine more than 90 ml/min ). In patients with severe renal failure (Cl creatinine less than 30 ml/min), plasma Css and final T1/2 are 3 times higher than in patients with normal renal function. The administration of multiple doses of moxonidine leads to predictable accumulation in the body of patients with moderate and severe renal failure. In patients with end-stage renal failure (Cl creatinine less than 10 ml/min) on hemodialysis, plasma Css and final T1/2 are 6 and 4 times higher, respectively, than in patients with normal renal function. In all groups, the Cmax of moxonidine in blood plasma is 1.5–2 times higher. In patients with impaired renal function, the dosage should be adjusted individually. Moxonidine is excreted to a small extent during hemodialysis.

Moxonidine analogs

Pharmacies offer a large selection of Moxonidine analogues Canon and North Star (SZ). The drugs differ in their basic composition, packaging and manufacturers. The selection of funds is carried out exclusively by a cardiologist.

SPTs of Moxonidine analogues with prices

Moxonidine or Physiotens - which is better and more effective, what is the difference

Manufacturer: Abbott Laboratories EPD, Russia
Release form: tablets

Active ingredient: moxonidine

Physiotens is a domestic analogue of Moxonidine, which is an antihypertensive agent. The mechanism of action depends on the main component. With regular use of the drug, a gradual decrease in blood pressure is observed.

After consumption, it is quickly and almost completely absorbed in the upper gastrointestinal tract. A distinctive feature of the Russian analogue is its inflated cost.

Reviews from doctors about these drugs for arterial hypertension are positive, as they help cope with the problem, stabilize the condition and have the same active ingredient.

Moxonidine Canon

Suction

After oral administration, moxonidine is rapidly and almost completely absorbed from the upper gastrointestinal tract. Absolute bioavailability is approximately 88%, indicating no significant first pass effect.

The time to reach maximum concentration is about 1 hour. Food intake does not affect the pharmacokinetics of the drug.

Distribution

The binding to plasma proteins is 7.2%.

Metabolism

The main metabolite is dehydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine is about 10% compared to moxonidine.

Removal

The half-life (7%) of moxonidine and metabolite is 2.5 and 5 hours, respectively. Within 24 hours, more than 90% of moxonidine is excreted by the kidneys (about 78% unchanged and 13% as dehydrated moxonidine, other metabolites in the urine do not exceed 8% of the dose taken). Less than 1% of the dose is excreted through the intestines.

Pharmacokinetics in patients with arterial hypertension

Compared with healthy volunteers, patients with arterial hypertension show no changes in the pharmacokinetics of moxonidine.

Pharmacokinetics in old age

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine were noted in elderly patients, probably due to a decrease in the intensity of its metabolism and/or slightly higher bioavailability.

Pharmacokinetics in children

Moxonidine is not recommended for use in persons under 18 years of age, and therefore pharmacokinetic studies have not been conducted in this group.

Pharmacokinetics in renal failure

Moxonidine excretion is significantly correlated with creatinine clearance (CC). In patients with moderate renal failure (CR in the range of 30-60 ml/min), steady-state plasma concentrations and terminal half-life (T1/2) are approximately 2 and 1.5 times higher than in persons with normal renal function (CR more than 90 ml/min).

In patients with severe renal failure (creatinine clearance less than 30 ml/min), steady-state plasma concentrations and terminal half-life (T1/2) are 3 times higher than in patients with normal renal function.

The administration of multiple doses of moxonidine leads to predictable accumulation in the body of patients with moderate and severe renal failure.

In patients with end-stage renal failure (creatinine clearance less than 10 ml/min) on hemodialysis, steady-state plasma concentrations and terminal half-life (T1/2) are 6 and 4 times higher, respectively, than in patients with normal renal function. .

In patients with moderate renal failure, the maximum concentration of moxonidine in the blood plasma is 1.5-2 times higher.

In patients with impaired renal function, the dosage should be adjusted individually. Moxonidine is excreted to a small extent during hemodialysis.

Moxonidine or Capoten - which is better during a crisis

Manufacturer: AKRIKHIN, Russia
Release form: tablets

Active ingredient: captopril

Kapoten is a domestically produced substitute for Moxonidine. This is a prescription drug that is an ACE inhibitor. The positive effect of administration and stabilization of the patient’s condition is observed 60–90 minutes after ingestion.

The drug is prescribed to patients of the older age category. Moxonidine analogue SZ Kapoten has an extensive list of indications, which include:

1. High blood pressure.
2. Chronic heart failure (CHF).
3. Coronary heart disease (CHD).
4. Diabetic nephropathy in insulin-dependent diabetes mellitus.

In case of hypertensive crisis, it is allowed to use both Moxonidine and its analogue Capoten.

Moxonidine or Captopril - which is better during a crisis

Manufacturer: SANDOS, Germany
Release form: tablets

Active ingredient: captopril

If you don’t know how to replace Moxonidine for hypertension, then use the ACE inhibitor – Captopril. It is an antihypertensive agent that has a vasodilator effect. If you take the tablets for a long time, the severity of left ventricular myocardial hypertrophy decreases. The drug has a vasodilating effect mainly on the arteries and improves blood supply to the ischemic myocardium.

Indications for the use of this cheap analogue of Moxonidine are related to the pharmacology of this drug:

1. High blood pressure.
2. CHF (chronic heart failure).
3. Impaired left ventricular functionality after myocardial infarction.
4. Diabetic nephropathy in type 1 diabetes mellitus.

In case of hypertensive crisis, experts recommend taking an imported analogue of the drug Moxonidine - Captopril. This is explained by the fact that the drug has extensive indications and effective pharmacological action, as well as positive reviews.

Moxonidine or Moxonitex – which is better?

Manufacturer: SANDOS, Germany
Release form: tablets

Active ingredient: moxonidine

Moxonitex is a foreign, prescription analogue. The drug is a selective agonist of imidazoline receptors. If you take the drug for a long time, the risk of developing left ventricular myocardial hypertrophy is reduced. Has no effect on heart rate.

After consuming the tablet, the patient’s condition stabilizes within 30–60 minutes. The duration of action is more than 12 hours.

The analogue is prescribed to patients of the older age group exclusively with high blood pressure.

Moxonidine or Moxarel – which is better?

Manufacturer: VETEKS, Russia
Release form: tablets

Active ingredient: moxonidine

Moxarel is an analogue of the active substance. It has antihypertensive properties with a central mechanism of action. Does not develop a sedative effect. After oral administration, dryness of the oral mucosa is not observed. The drug reduces systemic vascular resistance and blood pressure.

Prescribed to patients of the older age group with hypertension. The duration of the course and dosage are adjusted by the cardiologist depending on the general condition.

Self-therapy should be completely excluded, as this will lead to negative consequences.

Moxonidine Canon (0.2 mg, 0.3 mg, 0.4 mg)

Pharmacodynamics

Moxonidine is an antihypertensive drug with a central mechanism of action. In the brain stem structures (rostral layer of the lateral ventricles), moxonidine selectively stimulates imidazoline-sensitive receptors that take part in the tonic and reflex regulation of the sympathetic nervous system. Stimulation of imidazoline receptors reduces peripheral sympathetic activity and blood pressure (BP).

Moxonidine differs from other sympatholytic antihypertensive drugs in its lower affinity for α2-adrenergic receptors, which explains the lower likelihood of developing sedation and dry mouth.

Taking moxonidine leads to a decrease in systemic vascular resistance and blood pressure. The hypotensive effect of moxonidine has been confirmed in double-blind, placebo-controlled, randomized studies.

The results of a clinical trial involving 42 patients with arterial hypertension and left ventricular hypertrophy (LVH) demonstrated that, with a similar reduction in blood pressure, the use of a combination of angiotensin II receptor antagonists with moxonidine allowed a greater reduction in LVH compared with a free combination of a thiazide diuretic and a blocker. slow" calcium channels (15% versus 11%; p? 0.05).

Moxonidine improves the insulin sensitivity index by 21% (compared to placebo) in patients with obesity, insulin resistance and moderate hypertension.

Pharmacokinetics

Suction

After oral administration, moxonidine is rapidly and almost completely absorbed from the upper gastrointestinal tract. Absolute bioavailability is approximately 88%, indicating no significant first pass effect.

The time to reach maximum concentration is about 1 hour. Food intake does not affect the pharmacokinetics of the drug.

Distribution

The binding to plasma proteins is 7.2%.

Metabolism

The main metabolite is dehydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine is about 10% compared to moxonidine.

Removal

The half-life (T?) of moxonidine and metabolite is 2.5 and 5 hours, respectively. Within 24 hours, more than 90% of moxonidine is excreted by the kidneys (about 78% unchanged and 13% as dehydrated moxonidine, other metabolites in the urine do not exceed 8% of the dose taken). Less than 1% of the dose is excreted through the intestines.

Pharmacokinetics in patients with arterial hypertension

Compared with healthy volunteers, patients with arterial hypertension show no changes in the pharmacokinetics of moxonidine.

Pharmacokinetics in old age

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine were noted in elderly patients, probably due to a decrease in the intensity of its metabolism and/or slightly higher bioavailability.

Pharmacokinetics in children

Moxonidine is not recommended for use in persons under 18 years of age, and therefore pharmacokinetic studies have not been conducted in this group.

Pharmacokinetics in renal failure

Moxonidine excretion is significantly correlated with creatinine clearance (CC). In patients with moderate renal failure (creatinine clearance in the range of 30-60 ml/min), steady-state plasma concentrations and final half-life (T?) are approximately 2 and 1.5 times higher than in individuals with normal renal function (creatinine clearance more than 90 ml/min).

In patients with severe renal failure (creatinine clearance less than 30 ml/min), steady-state plasma concentrations and terminal half-life (T) are 3 times higher than in patients with normal renal function.

The administration of multiple doses of moxonidine leads to predictable accumulation in the body of patients with moderate and severe renal failure.

In patients with end-stage renal failure (creatinine clearance less than 10 ml/min) on hemodialysis, steady-state plasma concentrations and terminal half-life (T) are 6 and 4 times higher, respectively, than in patients with normal renal function. In patients with moderate renal failure, the maximum concentration of moxonidine in the blood plasma is 1.5-2 times higher. In patients with impaired renal function, the dosage should be adjusted individually. Moxonidine is excreted to a small extent during hemodialysis.

Which is better: Moxonidine or Moxonidine Canon

Manufacturer: KANOPHARMA, Russia
Release form: tablets

Active ingredient: moxonidine

Moxonidine Canon is a selective imidazoline receptor agonist. The drug is able to reduce systolic and diastolic blood pressure even after a single dose. Has no effect on heart rate. If the drug is used for a long time, the risk of left ventricular myocardial hypertrophy is reduced.

It is also prescribed to patients over 18 years of age with high blood pressure.

The main difference between Moxonidine Canon and Moxonidine SZ is the cost: the latter is a third more expensive.

Moxonidine canon 0.4 mg 60 pcs. film-coated tablets

pharmachologic effect

Centrally acting antihypertensive agent.

Composition and release form Moxonidine canon 0.4 mg 60 pcs. film-coated tablets

Tablets - 1 tablet:

• active substance - moxonidine 0.4 mg;
• excipients: hyprolose (hydroxypropylcellulose) 4.2 mg, mannitol 95 mg, croscarmellose sodium 4.7 mg, magnesium stearate 0.7 mg, microcrystalline cellulose 35 mg;
• composition of the film shell: Opadry II pink 4 mg, including polyvinyl alcohol 1.6 mg, macrogol (polyethylene glycol) 0.808 mg, talc 0.592 mg, titanium dioxide 0.9608 mg, sunset yellow dye 0.0004 mg, indigo carmine dye 0.0060 mg, crimson dye [Ponceau 4R] 0.0328 mg.

Film-coated tablets 0.4 mg.

7, 10, 28 or 30 tablets in a blister pack in polyvinyl chloride film and printed varnished aluminum foil.

2, 4, 6, 8 blister packs of 7 tablets each, or 1,2, 3, 4, 6 blister packs of 10 tablets each, or 1,2 blister packs of 28 tablets each, or 1, 2, 3, 4 blister packs of 30 tablets, together with instructions for use, are placed in a cardboard pack.

Description of the dosage form

The tablets are round, biconvex, pink film-coated. Almost white in cross section. Minor roughness is allowed.

Directions for use and doses

Inside, regardless of food intake, with a sufficient amount of liquid.

In most cases, the initial dose of Moxonidine Canon is 0.2 mg per day, in one dose, preferably in the morning. If the therapeutic effect is insufficient, the dose can be increased after 3 weeks of therapy to 0.4 mg per day, which should be divided into 2 doses (morning and evening) or once.

The maximum daily dose, which should be divided into 2 doses (morning and evening), is 0.6 mg.

The maximum single dose is 0.4 mg.

In elderly patients with normal renal function, dosage recommendations are the same as for adult patients.

In patients with renal failure (creatinine clearance 30-60 ml/min) and patients on hemodialysis, a single dose should not exceed 0.2 mg, the maximum daily dose is 0.4 mg.

Pharmacodynamics

Selective agonist of imidazoline receptors responsible for tonic and reflex control of the sympathetic nervous system (localized in the venterolateral medulla oblongata). Reduces the pressor effect of the sympathetic system on peripheral vessels, reduces peripheral vascular resistance, reduces systolic and diastolic pressure both with single and long-term administration, while cardiac output and heart rate (HR) do not change significantly. With long-term use, it reduces left ventricular myocardial hypertrophy, eliminates signs of myocardial fibrosis, microarteriopathy, and normalizes capillary blood supply to the myocardium. During treatment, the activity of norepinephrine and epinephrine, renin, angiotensin II at rest and during exercise, atrial natriuretic peptide (with exercise) and plasma aldosterone decreases.

It has a lower affinity for alpha2-adrenergic receptors, which explains the lower likelihood of developing sedation and dry mouth.

Reduces tissue resistance to insulin. Does not affect the metabolism of glucose and lipids.

Pharmacokinetics

Absorption after oral administration is 90%. Food intake does not affect the amount of absorption. Bioavailability - 88%.

Communication with blood plasma proteins - 7.2%. The maximum concentration (Cmax) in plasma is determined 30-180 minutes after oral administration and is 1-3 ng/ml. Volume of distribution - 1.4-3 l/kg.

The main metabolite is dihydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine is about 10% compared to moxonidine. Penetrates the blood-brain barrier. Does not accumulate with prolonged use.

The half-life of moxonidine and metabolites is 2.5 and 5 hours, respectively. Within 24 hours, more than 90% of moxonidine is excreted by the kidneys (78% unchanged, 13% as dihydrogenated moxonidine, 8% as other metabolites). Less than 1% of the dose is excreted through the intestines. Moxonidine is excreted to a small extent during hemodialysis.

Pharmacokinetics in patients with arterial hypertension

In patients with arterial hypertension, no changes in the pharmacokinetics of moxonidine are observed.

Pharmacokinetics in elderly patients

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine were noted in elderly patients, probably due to a decrease in the intensity of its metabolism and/or slightly higher bioavailability.

Pharmacokinetics in renal failure

Moxonidine excretion is significantly correlated with creatinine clearance (CC).

In patients with moderate renal failure (creatinine clearance in the range of 30-60 ml/min), steady-state plasma concentrations and terminal half-life are approximately 2 and 1.5 times higher than in patients with normal renal function (creatinine clearance more than 90 ml/min ).

In patients with severe renal failure (creatinine clearance less than 30 ml/min), steady-state plasma concentrations and terminal half-life are 3 times higher than in patients with normal renal function.

In patients with end-stage renal failure (creatinine clearance less than 10 ml/min) on hemodialysis, steady-state plasma concentrations and terminal half-life are, respectively, 6 and 4 times higher than in patients with normal renal function.

In patients with impaired renal function, the dosage should be adjusted individually.

Indications for use Moxonidine canon 0.4 mg 60 pcs. film-coated tablets

Arterial hypertension.

Contraindications

• Hypersensitivity to the components of the drug;
• severe heart rhythm disturbances;
• sick sinus syndrome;
• sinoatrial and atrioventricular blockade of II and III degrees;
• severe bradycardia (heart rate less than 50 beats/min);
• acute and chronic heart failure of functional class III and IV according to the NYHA classification;
• history of angioedema;
• severe liver failure (more than 9 points on the Child-Pugh scale);
• chronic renal failure (creatinine clearance less than 30 ml/min, creatinine more than 60 µmol/l);
• hemodialysis;
• simultaneous use of tricyclic antidepressants;
• age under 18 years (efficacy and safety have not been established);
• age over 75 years;
• lactation period.

Carefully -

• Parkinson's disease (severe form);
• epilepsy;
• glaucoma;
• depression;
• "intermittent" claudication;
• Raynaud's disease;
• atrioventricular block of the first degree;
• chronic renal failure (creatinine clearance more than 30 ml/min, but less than 60 ml/min);
• severe cerebrovascular disorders;
• after myocardial infarction;
• severe diseases of the coronary vessels;
• severe coronary heart disease or unstable angina (insufficient experience);
• chronic heart failure of functional class I and II according to the NYHA classification;
• liver dysfunction;
• pregnancy.

Application Moxonidine canon 0.4 mg 60 pcs. film-coated tablets during pregnancy and breastfeeding

There is no clinical evidence of a negative effect on pregnancy. However, Moxonidine Canon should be prescribed to pregnant women only if the potential benefit to the mother outweighs the possible risk to the fetus.

Moxonidine passes into breast milk, so if taking Moxonidine Canon is necessary during lactation, breastfeeding should be stopped.

special instructions

If it is necessary to cancel simultaneously taken beta-blockers and the drug Moxonidine Canon, first cancel the beta-blockers and only after a few days the drug Moxonidine Canon.

It is not recommended to prescribe tricyclic antidepressants simultaneously with Moxonidine Canon.

During treatment, regular monitoring of blood pressure, heart rate and ECG is necessary.

The drug Moxonidine Canon can be prescribed with thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors and blockers of “slow” calcium channels.

You should stop taking Moxonidine Canon gradually.

Impact on the ability to drive vehicles and operate machinery

Taking into account the possible occurrence of drowsiness and dizziness during treatment with Moxonidine Canon, patients should be careful when engaging in potentially hazardous activities that require increased attention, such as driving a vehicle or operating equipment that requires increased concentration.

Overdose

Symptoms: headache, sedation, drowsiness, marked decrease in blood pressure, dizziness, general weakness, bradycardia, increased fatigue, dry oral mucosa, vomiting and stomach pain. Paradoxical increases in blood pressure, tachycardia, and hyperglycemia are also potentially possible.

Treatment: there is no specific antidote. Gastric lavage (immediately after administration), taking activated charcoal and laxatives, symptomatic therapy.

In the case of a pronounced decrease in blood pressure, it is recommended to restore circulating blood volume by administering fluids and administering dopamine. Bradycardia can be relieved with atropine.

Alpha-adrenergic receptor antagonists can reduce or eliminate transient arterial hypertension following an overdose of Moxonidine Canon.

Side effects Moxonidine canon 0.4 mg 60 pcs. film-coated tablets

WHO classification of the incidence of side effects - very often - ≥1/10 prescriptions (>10%); often - from ≥1/100 to 1% and 0.1% and 0.01% and

Mental disorders: Often - decreased concentration; Uncommon: depression, anxiety, nervousness.

Disorders of the central nervous system: Often - increased fatigue, drowsiness, headache, dizziness; Uncommon: paresthesia, insomnia, fainting.

Gastrointestinal disorders: Often - dry oral mucosa, constipation, dyspeptic disorders; Uncommon: nausea, anorexia; Very rarely - hepatitis, cholestasis.

Disorders of the skin and subcutaneous tissues: Uncommon - skin rash, itching, swelling of various locations; Very rarely - angioedema.

Disorders of the genitourinary system: Uncommon - urinary retention or incontinence, impotence, decreased libido.

Disorders of the liver and biliary tract: Rarely - hepatitis, bile stagnation.

Eye disorders: Uncommon: dry eyes, causing itching or burning sensation in the eyes.

Hearing and labyrinthine disorders: Uncommon: tinnitus.

Vascular disorders: Often - symptoms of vasodilation; Uncommon: decreased blood pressure (BP), orthostatic hypotension, Raynaud's syndrome, peripheral circulation disorders.

Endocrine system disorders: Uncommon: gynecomastia.

Musculoskeletal and connective tissue disorders: Often - back pain; Uncommon: neck pain.

General disorders and disorders at the injection site: Often - asthenia; Uncommon: weakness in the legs, fainting, pain in the parotid glands.

Drug interactions

Moxonidine Canon can be prescribed with thiazide diuretics and slow calcium channel blockers. The combined use of the drug Moxonidine Canon with these and other antihypertensive drugs leads to an additive effect and increased hypotensive effect.

When prescribing Moxonidine Canon with hydrochlorothiazide, glibenclamide (glyburide) or digoxin, there is no pharmacokinetic interaction.

Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive drugs, so their simultaneous use is not recommended.

The drug Moxonidine Canon moderately enhances reduced cognitive ability in patients taking lorazepam.

Prescribing the drug Moxonidine Canon together with benzodiazepine derivatives may be accompanied by an increase in the sedative effect of the latter.

The drug Moxonidine Canon enhances the inhibitory effect on the central nervous system of anxiolytics, barbiturates and ethanol.

Beta-blockers, when used together with moxonidine, increase bradycardia and the severity of negative ino- and dromotropic effects.

When prescribing Moxonidine Canon together with moclobemide, there is no pharmacodynamic interaction.

Nifedipine

Manufacturer: OZON, Russia
Release form: tablets

Active ingredient: nifedipine

Nifedipine is a prescription drug, an inexpensive analogue. The composition includes the active ingredient of the same name. The drug is a selective class 2 calcium channel blocker. Has antianginal and hypotensive effects. Has almost no antiarrhythmic activity.

Prescribed for the prevention of angina attacks, as well as for arterial hypertension, hypertensive crisis and Raynaud's disease.

Moxonidine analogues are antihypertensive drugs that are recommended for patients in the older age group with high blood pressure. Most substitutes have extended indications that are related to pharmacology and active ingredients.

Moxonidine

Moxonidine is an antihypertensive drug belonging to the group of selective imidazoline receptor agonists. Arterial hypertension is the most common disease in our country. This can be judged at least by the steadily increasing frequency of ambulance calls during hypertensive crises. In this regard, adequate pharmacotherapy becomes more important than ever. Unfortunately, some antihypertensive drugs, while effectively lowering blood pressure, can cause adverse metabolic effects, which somewhat narrows the prospects for their further use. An example is beta-blockers, which, along with successfully reducing excessive activity, hyperactivity of the sympathetic nervous system can contribute to the occurrence of hypoglycemia in people with diabetes. In addition to this fly in the ointment, taking beta-blockers can provoke bronchospasm and worsen the prognosis in patients with bronchial asthma and chronic obstructive pulmonary disease. Due to the large role of sympathetic hyperactivity in the development of arterial hypertension, a new generation of symptatolytics, one of which is moxonidine, has recently been increasingly introduced into cardiological practice. Sympatholytics reduce blood pressure by selectively acting on the vasomotor centers of the medulla oblongata, which regulate the tone of the sympathetic nervous system. The “pioneers” of this pharmacological group were clonidine and methyldopa, and later second-generation drugs appeared, including moxonidine. Unlike first generation sympatholytics, it has a low degree of affinity for alpha-2 adrenergic receptors localized in the brain stem, which significantly reduces the risk of side effects, including dry mouth and sedation. The selectivity of the drug for I1-imidazoline receptors is more than 70 times greater than that for alpha2-adrenergic receptors.

At recommended doses, moxonidine is devoid of clinically significant side effects and causes a dose-dependent decrease in blood pressure, while the heart rate remains virtually unchanged. After discontinuation of moxonidine, the development of withdrawal syndrome is uncharacteristic. The drug reduces the concentration of renin, angiotensin II and aldosterone in the blood, which is of particular importance for the prevention of the development and progression of pathological changes in the heart and blood vessels. Relief of sympathetic hyperactivity under the influence of moxonidine is accompanied by a decrease in tissue insulin resistance and normalization of carbohydrate and lipid metabolism. In this regard, moxonidine is rightfully considered the drug of choice for the treatment of arterial hypertension in diabetics and people with metabolic syndrome. According to clinical trials, the antihypertensive activity of the drug is quite comparable to that of beta-blockers, diuretics, slow calcium channel blockers and ACE inhibitors. Moxonidine acts in two directions: on the cerebral sympathetic centers (short-term blood pressure control) and on renin release and renal excretory function (long-term blood pressure control). The drug has another interesting feature: it is more effective in patients with initially higher blood pressure levels. Therefore, the prospect of its use in hypertensive crises is of particular interest. A positive effect of moxonidine on the course of arterial hypertension in patients with chronic obstructive pulmonary disease was also revealed. Thus, moxonidine is a universal antihypertensive drug that is effective both in hypertensive crises and over a longer “distance”.